Oncology Drug Discovery

Reborn Through Science.

Accelerating the next generation of cancer therapeutics through deep scientific expertise, AI-augmented strategy, and end-to-end program partnership.

What We Do

End-to-End Consulting for Drug Development

01

Preclinical Pharmacology

Rigorous in vitro and in vivo study design, execution oversight, and data interpretation to de-risk your oncology program before IND.

02

AI Drug Development

Leveraging machine learning and computational biology to identify targets, optimize candidates, and predict clinical outcomes with greater precision.

03

Scientific Operations

Streamlining CRO management, data governance, and program coordination to keep your preclinical program on time and on budget.

04

Commercial Strategy

Translating scientific value into compelling narratives for investors, partners, and regulators — from pitch decks to regulatory strategy.

20+Years in Oncology Drug Development

Renaistre Scientific was founded on a singular belief: that the best science deserves the best strategy. We partner with biotech and pharma companies at every stage — from target identification to IND-enabling studies — bringing deep oncology expertise and AI-powered insights to every engagement.

Learn More About Us→
Why Renaistre
01

Deep Scientific Expertise

Decades of hands-on oncology research and drug development experience across multiple tumor types and modalities.

02

AI-Augmented Strategy

Proprietary computational approaches that accelerate decision-making and reduce the cost of failure.

03

End-to-End Partnership

From early discovery through clinical readiness — a single trusted partner across the full development arc.

Ready to Accelerate Your Program?

Let's discuss how Renaistre Scientific can help you move faster, smarter, and with greater confidence.

Renaistre Scientific

Drug Development and scientific Consultation

© 2026 Renaistre Scientific. All rights reserved.

Transforming Scientific Consultative Services